Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 8, Issue 20
October 22 2024
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

Tyrosine kinase inhibitor for CML: all the same?
Clinical Trials & Observations
Lukas Veltmaat,Jorge Cortes
View Articletitled, Tyrosine kinase inhibitor for CML: all the same?
CARs to the rescue: rare aggressive lymphoma gets a power up
Clinical Trials & Observations
Manali Kamdar
View Articletitled, CARs to the rescue: rare aggressive lymphoma gets a power up
Too short or unnecessarily long: walking the fine line
Chiranjeevi Sainatham,Tania Jain
View Articletitled, Too short or unnecessarily long: walking the fine line
What makes a good Samaritan: age, HLA matching, or both?
Clinical Trials & Observations
Pietro Crivello
View Articletitled, What makes a good Samaritan: age, HLA matching, or both?

CLINICAL TRIALS AND OBSERVATIONS

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera
Clinical Trials & Observations
Anders Lindholm Sørensen,Vibe Skov,Lasse Kjær,Mads Emil Bjørn,Christina Schjellerup Eickhardt-Dalbøge,Morten Kranker Larsen,Claus H Nielsen,Carsten Thomsen,Lise Mette Rahbek Gjerdrum,Trine Alma Knudsen,Christina Ellervik,Ulrik Malthe Overgaard,Christen Lykkegaard Andersen,Hans Hasselbalch
View Articletitled, Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera
Supplemental data

HEALTH SERVICES AND OUTCOMES

Impact of an individualized pain plan to treat sickle cell disease vaso-occlusive episodes in the emergency department
Clinical Trials & Observations
Lauren Siewny,Allison King,Cathy L. Melvin,Christopher R. Carpenter,Jane S. Hankins,Joseph S. Colla,Liliana Preiss,Lingzi Luo,Lisa Cox,Marsha Treadwell,Natalia Davila,Rita V. Masese,Sarah McCuskee,S. Siera Gollan,Paula Tanabe,for the Sickle Cell Disease Implementation Consortium
View Articletitled, Impact of an individualized pain plan to treat sickle cell disease vaso-occlusive episodes in the emergency department
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Targeting CDC42 reduces skeletal degeneration after hematopoietic stem cell transplantation
Theresa Landspersky,Merle Stein,Mehmet Saçma,Johanna Geuder,Krischan Braitsch,Jennifer Rivière,Franziska Hettler,Sandra Romero Marquez,Baiba Vilne,Erik Hameister,Daniel Richter,Emely Schönhals,Jan Tuckermann,Mareike Verbeek,Peter Herhaus,Judith S. Hecker,Florian Bassermann,Katharina S. Götze,Wolfgang Enard,Hartmut Geiger,Robert A. J. Oostendorp,Christina Schreck
View Articletitled, Targeting CDC42 reduces skeletal degeneration after hematopoietic stem cell transplantation
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function
Jean-Benoît Le Luduec,Theodota Kontopoulos,M. Kazim Panjwani,Rosa Sottile,Hongtao Liu,Gesine Schäfer,Carolin Massalski,Vinzenz Lange,Katharine C. Hsu
View Articletitled, Polygenic polymorphism is associated with NKG2A repertoire and influences lymphocyte phenotype and function
Supplemental data

LYMPHOID NEOPLASIA

Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies
Nardjas Bettazova,Jana Senavova,Kristyna Kupcova,Dana Sovilj,Anezka Rajmonova,Ladislav Andera,Karla Svobodova,Adela Berkova,Zuzana Zemanova,Lenka Daumova,Vaclav Herman,Alexandra Dolníkova,R. Eric Davis,Marek Trneny,Pavel Klener,Ondrej Havranek
View Articletitled, Impact of <em>PIK3CA</em> gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies
Supplemental data
CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma
Priyanka A. Pophali,Joshua A. Fein,Kwang W. Ahn,Molly Allbee-Johnson,Nausheen Ahmed,Farrukh T. Awan,Shatha Farhan,Natalie S. Grover,Talal Hilal,Madiha Iqbal,Joseph Maakaron,Dipenkumar Modi,Elham Nasrollahi,Levanto G. Schachter,Craig Sauter,Mehdi Hamadani,Alex Herrera,Roni Shouval,Mazyar Shadman
View Articletitled, CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma
Supplemental data
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
Nausheen Ahmed,William Wesson,Forat Lutfi,David L. Porter,Veronika Bachanova,Loretta J. Nastoupil,Miguel-Angel Perales,Richard T. Maziarz,Jamie Brower,Gunjan L. Shah,Andy I. Chen,Olalekan O. Oluwole,Stephen J. Schuster,Michael R. Bishop,Joseph P. McGuirk,Peter A. Riedell
View Articletitled, Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
Supplemental data
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Narendranath Epperla,Adam S. Zayac,Daniel J. Landsburg,Allison M. Bock,Grzegorz S. Nowakowski,Emily C. Ayers,Mark Girton,Marie Hu,Amy Beckman,Shaoying Li,L. Jeffrey Medeiros,Julie E. Chang,Habibe Kurt,Jose Sandoval-Sus,Mohammad Ali Ansari-Lari,Shalin K. Kothari,Anna Kress,Mina L. Xu,Pallawi Torka,Suchitra Sundaram,Stephen D. Smith,Kikkeri N. Naresh,Yasmin Karimi,David A. Bond,Andrew M. Evens,Seema G. Naik,Manali Kamdar,Bradley M. Haverkos,Reem Karmali,Umar Farooq,Julie M. Vose,Paul Rubinstein,Amina Chaudhry,Adam J. Olszewski
View Articletitled, High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Supplemental data
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy
Vincent Camus,Roch Houot,Gabriel Brisou,Benoit Tessoulin,Sébastien Bailly,Pierre Sesques,Justine Decroocq,Daphné Krzisch,Lucie Oberic,François Lemonnier,Krimo Bouabdallah,Arnaud Campidelli,Ledraa Tounes,Julie Abraham,Charles Herbaux,Franck Morschhauser,Gandhi Laurent Damaj,Stéphanie Guidez,Sylvain Carras,Luc-Matthieu Fornecker,Sylvain Choquet,Olivier Hermine,Jérome Paillassa,Adrien Chauchet,Olivier Casasnovas,Laurianne Drieu La Rochelle,Cristina Castilla-Llorente,Magalie Joris,Vivien Dupont,Alexandra Marquet,Steven Le Gouill,Fabrice Jardin
View Articletitled, Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy
Supplemental data

MYELOID NEOPLASIA

Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study
Clinical Trials & Observations
Itaru Matsumura,Shigeki Ohtake,Yoshiko Atsuta,Mio Kurata,Yosuke Minami,Naoto Takahashi,Chiaki Nakaseko,Noriyoshi Iriyama,Katsumichi Fujimaki,Kazuhiko Kakihana,Yoji Ogasawara,Takaaki Ono,Masaya Okada,Tetsuzo Tauchi,Toshihiro Miyamoto,Kazunori Ohnishi,Emiko Sakaida,Shin Fujisawa,Yukio Kobayashi,Norio Asou,Tomoki Naoe,Hitoshi Kiyoi,Yasushi Miyazaki,for the Japan Adult Leukemia Study Group
View Articletitled, Nilotinib vs dasatinib in achieving MR<sup>4.5</sup> for de novo chronic myeloid leukemia: the randomized JALSG CML212 study
Supplemental data
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Fieke W. Hoff,William G. Blum,Ying Huang,Rina Li Welkie,Ronan T. Swords,Elie Traer,Eytan M. Stein,Tara L. Lin,Kellie J. Archer,Prapti A. Patel,Robert H. Collins,Maria R. Baer,Vu H. Duong,Martha L. Arellano,Wendy Stock,Olatoyosi Odenike,Robert L. Redner,Tibor Kovacsovics,Michael W. Deininger,Joshua F. Zeidner,Rebecca L. Olin,Catherine C. Smith,James M. Foran,Gary J. Schiller,Emily K. Curran,Kristin L. Koenig,Nyla A. Heerema,Timothy Chen,Molly Martycz,Mona Stefanos,Sonja G. Marcus,Leonard Rosenberg,Brian J. Druker,Ross L. Levine,Amy Burd,Ashley O. Yocum,Uma M. Borate,Alice S. Mims,John C. Byrd,Yazan F. Madanat
View Articletitled, Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Supplemental data
The E3 ubiquitin ligase Herc1 modulates the response to nucleoside analogs in acute myeloid leukemia
Maja Jankovic,William W. L. Poon,Cristobal Gonzales-Losada,Gabriela Galicia Vazquez,Bahram Sharif-Askari,Yi Ding,Constance Craplet-Desombre,Alexandru Ilie,Jiantao Shi,Yongjie Wang,Ashok Kumar Jayavelu,Alexandre Orthwein,François Émile Mercier
View Articletitled, The E3 ubiquitin ligase Herc1 modulates the response to nucleoside analogs in acute myeloid leukemia
Supplemental data

THROMBOSIS AND HEMOSTASIS

Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry
Innocent G. Asiimwe,Marc Blockman,Larisa H. Cavallari,Karen Cohen,Clint Cupido,Collet Dandara,Brittney H. Davis,Barry Jacobson,Julie A. Johnson,Mohammed Lamorde,Nita A. Limdi,Jennie Morgan,Johannes P. Mouton,Sarudzai Muyambo,Doreen Nakagaayi,Arinao Ndadza,Emmy Okello,Minoli A. Perera,Elise Schapkaitz,Christine Sekaggya-Wiltshire,Jerome R. Semakula,Gayle Tatz,Catriona Waitt,Guang Yang,Eunice J. Zhang,Andrea L. Jorgensen,Munir Pirmohamed
View Articletitled, Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry
Supplemental data
Proactive systematic hemophilia carrier screening: a step toward gender equity in hemophilia care
Evelien Krumb,Catherine Lambert,An Van Damme,Cedric Hermans
View Articletitled, Proactive systematic hemophilia carrier screening: a step toward gender equity in hemophilia care

TRANSPLANTATION

Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations
Rohtesh S. Mehta,Jeremy Ramdial,Partow Kebriaei,Richard E. Champlin,Uday Popat,Katayoun Rezvani,Elizabeth J. Shpall
View Articletitled, Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations
Supplemental data
Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT
Rohtesh S. Mehta,Effie W. Petersdorf,Tao Wang,Stephen R. Spellman,Stephanie J. Lee
View Articletitled, Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT
Supplemental data

RESEARCH LETTERS

COVID-19 vaccination during therapy in relation to COVID-19 death in CLL
Clinical Trials & Observations
Jennifer R. Brown,Simon Rule,Kara Miller,John F. Seymour
View Articletitled, COVID-19 vaccination during therapy in relation to COVID-19 death in CLL
Inhibition of MICA and MICB shedding enhances memory-like NK-cell–mediated cytotoxicity against multiple myeloma
Sabrin Tahri,Sara Piccinelli,Nang Kham Su,Luisa Lampe,Han Dong,Juliana Vergara Cadavid,Rebecca Boiarsky,Natalie Papazian,Elizabeth D. Lightbody,Amanda Cao,Jean-Baptiste Alberge,Lucas Ferrari de Andrade,Mahshid Rahmat,Yujia Shen,Laura Blanco Fernández,Aintzane Zabaleta,Andreas Günther,Gad Getz,Pieter Sonneveld,Tom Cupedo,Kai W. Wucherpfennig,Irene M. Ghobrial,Rizwan Romee
View Articletitled, Inhibition of MICA and MICB shedding enhances memory-like NK-cell–mediated cytotoxicity against multiple myeloma
Supplemental data
Biomarker-derived fast-and-frugal decision tree for preemption of veno-occlusive disease/sinusoidal obstructive syndrome
Sophie Paczesny,Iztok Hozo,Benjamin Djulbegovic
View Articletitled, Biomarker-derived fast-and-frugal decision tree for preemption of veno-occlusive disease/sinusoidal obstructive syndrome
Supplemental data

COMMENTARY

Nutritional intervention as adjuvant therapy for T-cell acute lymphoblastic leukemia
Clinical Trials & Observations
Miriam B. Garcia,Palaniraja Thandapani
View Articletitled, Nutritional intervention as adjuvant therapy for T-cell acute lymphoblastic leukemia

LETTER TO THE EDITOR

Accurate analysis of race/ethnicity and socioeconomic status
Clinical Trials & Observations
Warren B. Fingrut,Andromachi Scaradavou,Juliet N. Barker
View Articletitled, Accurate analysis of race/ethnicity and socioeconomic status

ERRATA

Hasselbalch HC, Kristiansen MH, Kjær L, et al. CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities. Blood Adv. 2024;8(3):681-682.
View Articletitled, Hasselbalch HC, Kristiansen MH, Kjær L, et al. CHIP-<em>JAK2V617F</em>, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities. <em>Blood Adv</em>. 2024;8(3):681-682.
Jerkeman M, Kolstad A, Hutchings M, et al. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood Adv. 2024;8(2):407-415.
View Articletitled, Jerkeman M, Kolstad A, Hutchings M, et al. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. <em>Blood Adv.</em> 2024;8(2):407-415.
Tarlock K, Gerbing RB, Ries RE, et al. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Adv. 2024;8(9):2094-2103.
View Articletitled, Tarlock K, Gerbing RB, Ries RE, et al. Prognostic impact of cooccurring mutations in <em>FLT3</em>-ITD pediatric acute myeloid leukemia. <em>Blood Adv.</em> 2024;8(9):2094-2103.
  • Cover Image

    Cover Image

    issue cover

    Persisting gender inequities in hemophilia care, from timely and accurate diagnosis to multidisciplinary care and access to both established and novel treatments. See the article by Krumb et al.

All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals